 DVFK-Delegation: Prof. H.-F. Vöhringer, Prof. H.V. Tien (Uni Hue), Prof. S.H. Nguyen, Dr. K. Schlotterbeck, Prof. H.V. Minh (Uni Hue) Dr. B. Gerecke, Prof. V. Klauss, Prof. T. Budde, Dr. D.Q. Nguyen VIETNAMESE GERMAN SYMPOSIUM Hue University of Medicine and Pharmacy 29.11.2013 08:00 - 13:00 Organization:
Lectures: Latest Important Clinical Trials in Cardiology (2012-2013) - An Overview Prof. Dr. med. Thomas Budde, F.E.S.C., European Cardiologist, Director, Department of Internal Medicine and Cardiology, Alfried Krupp Hospital, Alfried-Krupp-Straße 21, D-45117 Essen Phone: +49-201-434-2524/2525, Fax: +49-201-434-2376 E-mail: [email protected] Introduction: Purpose of this presentation is to give an overview about the latest cardiologic trials published in years 2012-2013. Only trials with direct, major relevance for everyday clinical practice are selected. This selection is part of a periodic lecture program of the academy of the German Cardiologic Society (DGK). Selected Trials/Publications: KERALA ACS Registry (25.478 consecutive pts. with ACS in Kerala/India, 2007-2009, 125 hospitals; thrombolysis vs. PCI; analysis of hospital admission and treatment modalities, in-hospital mortality and MACE-rates) (Eur Heart J 2013; 34:121-129)) SCAAR= Swedisch Coronary Angiography and Angioplasty Registry (64.436 pts.; coronary angiography in ACS; 54.419 (84.4%) of patients with significant coronary stenosis; analysis of mortality with BMI (body mass index) as a continuous variable. Findings in context of the `obesity paradox`) (Eur Heart J 2013; 34:345-353); Metaanalysis of Stent Thrombosis after Coronary Intervention: Drug Eluting Stents (DES) (49 studies, >50.000 pts.; Everolimus: 16 studies / Paxitacel: 26 studies / Sirolimus: 20 studies; follow-up: 1-2 yrs., analysis for stent thrombosis after 30 days and 2 years) (Lancet 2012; 379:1393-1402); Pooled Data Analysis of the ISAR-TEST 3-, ISAR-TEST 4- and LEADERS-STUDY (Efficacy and clinical long-term results of biodegradable polymer stents vs. non biodegradable Sirolimus-eluting stents; pooling of the data of 3 large randomised multicenter trials; 4.062 pts; 2.358 biodegradable stents; follow-up: 4 years; analysis for late stent thrombosis and myocardial infarction) (Eur Heart J 2012; 33:1214-1222) ; Long-Term (>10 Years) Clinical Outcomes of First In-Human Biodegradable Poly-I-Lactic Acid Coronary Stents (50 pts.; 84 biodegradable Igaki-Tamai-Stents= bioresorbable Stents without drug elution; follow up >120 months; 87% survival; analysis for acute stent thrombosis and coronary re-interventions) (Circulation 2012; 125:2343-2352); RELY-ABLE (analysis of patients still being on study medication at the last check of the RELY-Study (pts. with atrial fibrillation; dabigatran vs. warfarin; 5.851 pts; median follow-up: 2.3 years; analysis for stroke, systemic embolism, major bleedings or deaths, resp., per year) (CirculationAHA 2013, published online before print); PROTECT-AF (707 pts.; non-valvular atrial fibrillation + at least 1 major risk factor for stroke; randomisation on closure of left atrial appendage (WatchmanR device) vs. Warfarin; endpoints: stroke, systemic embolism, death; non-inferiority trial) (Circulation 2013; 127:720-729); PARTNER Cohort A Trial (1.057 pts with severe aortic stenosis; 699 high-risk / 351 with contraindications for surgery; patients with high-risk randomised to surgery or TAVI (=transaortic valve implantation via catheter); follow-up > 3 years; analysis for endpoints of mortality, stroke, and other clinical factors) (1 year results: NEJM 2011 / 2 year results: NEJM 2012 / 3 year results: ACC meeting 2013, San Francisco; oral presentation); SYNTAX-Trial (1.800 pts.; 5 years-results; coronary bypass graft surgery vs. PCI in patients with three vessel- or left main coronary disease; endpoints: MACE, stroke, myocardial infarction, repeat revascularisation of target vessel, mortality) (Lancet 2013; 381:629-638); WOEST-Trial (573 pts; PCI in patients being on anticoagulant therapy; open-label, randomised, controlled trial; 284 pts. randomised to double therapy (anticoagulant + aspirin) vs. 289 pts randomised to triple therapy (anticoagulant + aspirin + clopidogrel); 1-year-results; analysis for stent thrombosis and a secondary combined endpoint of death, myocardial infarction, stroke or repaeat target vessel revascularisation) (Lancet 2013; 381:1107-1115). Summary: 10 recent cardiologic studies published 2012 to 2013 with great clinical impact were selected for this presentation. Topics/designs of the studies are listed above. The results of the studies will be explained and discussed during oral presentation. The presentation will be provided for the audience in digital format. Update on Differentiated Diagnosis and Risk Stratification of (Coronary) Heart Disease with a Special Focus on CT and MRI Prof. Dr. Thomas Budde, Medical Clinic I, Department of Cardiology, Alfried Krupp Hospital, Essen, Germany Introduction: Patient history, clinical risk factor assessment (including established scoring systems) and up-to-date non-invasive and/or invasive diagnostic strategies are fundamental for the diagnosis of coronary artery disease. These strategies include laboratory tests, electrocardiogram/echocardiogram at rest and under exercise, chest x-ray as well as cardio-CT or –MRI, nuclear cardiologic methods, invasive coronary angiography and intravascular ultrasound or Doppler. The use of the different methods is oriented to the clinical presentation of the patient and the pre-test probability of the presence or absence of significant CAD. Risk Stratification and Diagnosis: The pre-test probability of CAD can be estimated by the patient’s history (angina pectoris/dyspnoea/palpitations/nausea/faintness/syncope under rest and exercise?) and systematic risk factor analysis. Established risk factor scoring systems (e.g. FRAMINGHAM-/PROCAM-/EUROSCORE) can be helpful to characterize and quantify the individual risk of CAD in patients without a previous history of CAD or estimate the probability of coronary or other cardiac events in patients with known CAD. Whereas, in high risk situations or with clear clinical symptoms of CAD, the diagnostic algorithm will soon proceed to invasive coronary angiography, the low and very low risk situation will lead to non-invasive techniques and will more or less focus on analysis and modification of potentially existing risk factors. With intermediate pre-test probability of CAD, non-invasive techniques of coronary or myocardial imaging or tests to detect ischemia will be of high importance. Cardiac Computer Tomography (CT): Cardiac CT is able to detect coronary atherosclerosis by quantitative calcium scoring. High coronary calcium scores are related to the risk of chronic and acute coronary events, cardiac death and the development of significant coronary stenoses. Low or zero-calcium scores have a high negative predictive value (NPV) for excluding significant coronary artery disease. CT angiography may be a valuable tool for (1) exclusion of coronary artery disease prior to non-cardiac surgery in patients with intermediate cardiac risk, (2) patients with chronic angina pectoris with intermediate or low risk and inconsistent stress test results, (3) clarification of acute chest pain in patients with low or intermediate risk, normal ECG and normal laboratory results, (4) patients with newly developed heart failure without known CAD and low or intermediate coronary risk, (5) cases with suspected or known coronary anomaly, or (6) for sizing and planning before minimally invasive valve surgery. Cardiac MRI is able to visualize cardiac and coronary anatomy and to analyze ventricular wall motion and myocardial vitality (also in patients not suitable for echocardiography). With MRI stress testing techniques, functional aspects of ischemia and the need for interventional procedures can be guided. Late enhancement technique enables differentiating between (still) vital myocardial tissue and scar tissue. A negative stress-MRI is associated with a good long-term prognosis, whereas patient groups with inducible wall motion abnormalities in stress-MRI experience higher rates of myocardial infarction or cardiovascular death. The current clinical indications for cardiac MRI are: 1. Heart failure, 2. Coronary heart disease, 3. Valvular heart disease, 4. Diagnosis of cardiac masses, 5. Pericardial disease (constrictive pericarditis), 5. Congenital heart disease and 6. Pulmonary arterial disease or pulmonary embolism. Patients with new generations of cardiac pacemeakers may be no longer excluded from MRI imaging. Events and Prognosis in Noncompaction Cardiomyopathy - Data of the German Noncompaction Registry Dr. Birgit Gerecke, Prof. Dr. Rolf Engberding, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Isolated noncompaction cardiomyopathy (NCCM) is considered a primary genetic cardiomyopathy. Little is known about the prognosis of affected patients. The previous literature determines the prognosis by heart failure symptoms, varying arrhythmias and thrombembolic events, ranging from asymptomatic to maligne incidences. To further investigate this rare disease the German Noncompaction Registry (ALKK) was initiated in 2006. Patients were diagnosed by echocardiography having NCCM if at least four prominent trabeculations and deep intertrabecular recesses with blood flow from the LV cavity into the recesses were seen and if there was a typical bilaminar structure of the LV wall with an endocardial noncompacted layer (NC) and a compacted subepicardial layer (C) with NC>2xC. No other cardiac abnormalities should be present. By August 30th, 2013 the German NCCM registry had enrolled 320 patients (203 male, 117 female, age 18 to 88 years, mean age 52.9 years). The clinical data (functional status, medication, non pharmacological therapy) and clinical events (heart failure symptoms, any documented arrhythmias, embolic events) were reviewed, as were the ECG recordings and the echocardiography and MR images. As possible risk factors age, sex, severe heart failure symptoms (NYHA class III and IV), severely reduced LV ejection fraction (EF < 35%), LV dilatation (LVEDD > 5.5 cm), atrial fibrillation, LBBB and mitral regurgitation (> II°) were analysed. Heart failure symptoms (NYHA III/IV) were observed in 38% (122/320 pts). LBBB was seen in 21.8 %, atrial fibrillation in 19.1%, supraventricular tachycardia in 4%, bradycardia requiring a pacemaker system in 3.7 % and VT/VF in 14.7 % of the pts. 73 pts in the registry had an ICD implantation with primary (PP) or secondary (SP) preventive indication. 8 out of 38 pts with a PP indication in the group of pts with severely reduced LV function expired shock therapy, but none in the group with PP indication in the group with preserved LV function. There were 8.1 % deaths, 4% in pts with preserved LV function, 14.7 % in the group with EF < 35%. Age or sex could not be found as a risk factor for any event. No risk factor could be identified for thrombembolic events. LVEF < 35%, LV dilatation, atrial fibrillation. LBBB and mitral regurgitation were significant risk factors for a worse prognosis. Screening of the pts or relatives with NCCM should be performed for these parameters to induce proper therapy to enhance the prognosis. Seminar on Device Therapy: Indications for device therapy: update of ICD therapy , pacing and resynchronisation therapy 2013 Dr. Birgit Gerecke, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Endoscopically guided Isolation of the pulmonary veins: a new approach in catheter based therapy of atrial fibrillation Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Electric isolation of the pulmonary veins (PVs) can successfully treat patients with paroxysmal atrial fibrillation. However, it remains technically challenging to identify the left atrial-PV junction and sequentially position the ablation catheter in a point-by-point contiguous fashion to isolate the PVs. A novel endoscopic ablation system was used to directly visualize and ablate tissue at the left atrial-PV junction with laser energy. After transseptal puncture, the balloon-based endoscopic ablation system was advanced to each PV ostium, and arcs of laser energy (90 degrees to 360 degrees ) were projected onto the target left atrial-PV junction. Electric PV isolation was defined with a circular multielectrode catheter. The durability of pulmonary vein isolation was investigated in a study, which is published in Heart Rhythm, June 2012. Acute success rate (complete PV isolation) was 98%. After a follow up period of 3 months, 86% of the PVs remained isolated. We present 6 month follow up success-rate data, in comparison to the PVAC-procedure, an alternate single shot device. Catheter Ablation of ventricular tachycardia: an overview Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Ablation of life-threatening ventricular tachycardia is still challenging. The indications for interventional therapy of VT`s will increasing in according to the increasing number of ICD and CRT-D-implantations and consecutive detected and treated ventricular tachyarrhythmias. As we know, that ICD-interventions, adequate as well as inadequate, are related with increased morbidity and mortality, an aggressive antiarrhythmic regimen is necessary. The OPTIC study has shown a disappointing effectiveness of Antiarrhythmic drugs (amiodarone, sotalole, betablockers). Studies on VT-ablation (V-TACH) has shown good success rate in the interventional group. Therefore a large amount of catheter ablation strategies are published: 3-D-electroanatomically guided substrate modification, epicardial approach, identification of late potentials are some of the keywords in the modern ablation strategy for ventricular tachycardia. An overview. CRT-D: newest guidelines, developments Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Anticoagulation in Atrial Fibrillation: Update 2013 Dr. Alexander Trompler, ACCR, Ravensburg, Germany Anticoagulation therapy in atrial fibrillation (AF) is enhanced by the novel oral thrombin- and factor Xa- inhibitors (NOACs). Dabigatran, rivaroxaban, apixaban, and edoxaban have now been approved or are currently in late-stage clinical development in AF. Based on the recent updates of the european society of cardiology guidelines for the management of AF, risk stratification strategies to reduce thromboembolic events in patients with AF will be reviewed. A special focus will be on the use of the NOACs in different clinical settings, e.g. renal insufficiency, elderly patients and patients with high risk of bleeding. Diagnosis and treatment of pulmonary embolism: Role of echocardiography Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at Pham Ngoc Thach University of Medicine, HELIOS St. Marienberg Hospital Helmstedt, Academic Hospital of the University Magdeburg, Germany The pulmonary embolism is common and is a potentially life-threatening situation, especially if it is not recognized in time. In hemodynamically stable patients with suspected pulmonary embolism, CT pulmonary angiography is the gold standard for diagnostic imaging. In patients with acute hemodynamic deterioration with persistent arterial hypotension and/or cardiogenic shock of unknown cause must be thought generally to a differential diagnosis of pulmonary embolism. Echocardiography can shows indirect signs of pulmonary embolism (acute pulmonary hypertension and right ventricular overload or thromboembolic sources from the right heart) with possible different therapeutic consequences. Gender-specific aspects in the therapy of cardiovascular diseases Prof. Dr. Hans-F. Voehringer, DRK Kliniken Berlin, Germany Cardiovascular diseases (CVD) are a major cause of mortality and morbidity for men and women. In 2011, about 42 % of all females’ death in Europe are caused by CVD, especially coronary heart disease and stroke (14%). It has been suggested that there is a gender difference in the clinical manifestation of CVD’s and in the response to therapy. The pharmacological response may differ in women when compared to men because of different endogenous hormone levels, a lower body weight, and a higher proportion of fat. Gender differences in enzyme activities involved in drug metabolism as well as a lower glomerular filtration rate which influences drug elimination have been demonstrated. Despite these relevant pharmacokinetic differences among cardiovascular drugs the impact on pharmacodynamics is often unknown a/o cannot be elucidated. The benefit of aspirin in primary prevention of myocardial infarction is less clear for women. Meta-analyses of ACE-inhibitor therapy in heart failure show for women a tendency towards less effective mortality and morbidity reduction. Adverse drug reactions in form of ACE-inhibitor cough occur twice as frequently in women. Reduction in blood pressure through calcium channel blockers is more pronounced in women than in man. For cardiac glycosides, there is evidence of a higher mortality in female patients with chronic heart failure. Torsades de pointes tachycardia occur in women under Antiarrhythmics as well as Non-antiarrythmics significantly more frequent than in men. The lack of more conclusive data on the magnitude of gender differences in response to cardio-vascular therapies should stimulate basic and clinical research to advance the knowledge on this topic. Does OCT replace IVUS in the cath lab – what do we need for intervention? Dr. Klaus Schlotterbeck, FESC, MBA, Cardiovascular Center (ACCR), Ravensburg, Germany The gold standard for diagnostic imaging of the coronary arteries is still the angiography. Many limitations of this technique are known , so advancements have been developed. The use of intravascular ultrasound (IVUS) has enabled a transmural in vivo imaging of the coronary arteries while creating cross-sectional images of the vessel wall. The role of IVUS is to assess stent underexpansion and malapposition to identify coronary plaques with potential rupture, to plan intervention in complex cases, identify significant left main stem stenosis. The spectral analysis , derived from radiofrequency (RF) data enables more precise analysis of the plaque composition and plaque type. A new modality based on infrared light is the optical coherence tomography (OCT). With a resolution of 10-20 µm, which is better than IVUS this method provides intraluminal and extraluminal imaging of the vessels. Based on OCT it is able to distinguish between different tissue types, such as fibrous, lipid rich, necrotic or calcified tissue. OCT helps to assess patients with acute coronary syndrome with insights into plaque nature, rupture and progression. It also has been established as a gold standard for stent evaluation. Which stenosis should be treated? Lessions learned from coronary physiology Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany The decision for interventional treatment of a coronary lesion should be based on symptoms and prove of ischemia. However, in clinical practice, stenoses are often treated depending on the angiographic image, because symptoms are not clear and tests for ischemia have not been performed or the tests are inconclusive. By means of intracoronary pressure measurements (i.e. determination of fractional flow reserve - FFR) the hemodynamic relevance of a coronary stenosis can be determined during coronary angiography especially in intermediate lesions and thus the decision to treat or not to treat is based on an objective test of ischemia. Newer developments (instantaneous wave-free ratio – iFR) may facilitate the application of physiologic measurements in interventional cardiology. Surgery in acute endocarditis PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Treatment modalities for severe aortic stenosis - New technologies PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Faculty: PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Prof. Dr. Thomas Budde, Medical Clinic I, Department of Cardiology, Alfried Krupp Hospital, Essen, Germany Dr. Birgit Gerecke, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany Prof. Dr. Georg Dieter Kneissl Johannes Gutenberg-University Mainz, Germany Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at the Pham Ngoc Thach University of Medicine /HCM City, Academic Hospital HELIOS St. Marienberg Helmstedt, Germany Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Dr. Klaus Schlotterbeck, Cardiovascular Center (ACCR), Ravensburg, Germany Dr. Alexander Trompler, Cardiovascular Center (ACCR), Ravensburg, Germany Prof. Dr. Dr. Reinhard Urban, Johannes Gutenberg-University Mainz, Germany Prof. Dr. Hans-F. Voehringer, DRK Kliniken Berlin, Germany von li. nach re. 1.Reihe: Prof. V. Klauss (München), Prof. H.-F. Vöhringer (Berlin), Dr. B. Gerecke (Peine) 2. Reihe: Dr. K. Schlotterbeck (Ravensburg), Dr. D.Q. Nguyen (Köln), Prof. T. Budde (Essen)  Zur Bearbeitung hier klicken Prof. H.V. Minh (Uni Hue), Prof. D.D. Loi (Ha Noi), Prof. C.N. Thanh (Rektor der Uni Hue), Dr. N.T.T. Hoai (Ha Noi), Prof. S.H. Nguyen (DVFK), Prof. N.H.Thuy (Uni Hue)
0 Comments
3. VIETNAMESE GERMAN Scientific Symposium
Nha Trang 27.11.2013 KHANH HOA HOSPITAL 13:00 - 17:00 Organization:
Lectures: Latest Important Clinical Trials in Cardiology (2012-2013) - An Overview Prof. Dr. med. Thomas Budde, F.E.S.C., European Cardiologist, Director, Department of Internal Medicine and Cardiology, Alfried Krupp Hospital, Essen, Germany Update on Differentiated Diagnosis and Risk Stratification of (Coronary) Heart Disease with a Special Focus on CT and MRI Prof. Dr. Thomas Budde, Medical Clinic I, Department of Cardiology, Alfried Krupp Hospital, Essen, Germany Events and Prognosis in Noncompaction Cardiomyopathy - Data of the German Noncompaction Registry Dr. Birgit Gerecke, Prof. Dr. Rolf Engberding, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Seminar on Device Therapy: Indications for device therapy: update of ICD therapy , pacing and resynchronisation therapy 2013 Dr. Birgit Gerecke, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Endoscopically guided Isolation of the pulmonary veins: a new approach in catheter based therapy of atrial fibrillation Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Catheter Ablation of ventricular tachycardia: an overview Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany CRT-D: newest guidelines, developments Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Anticoagulation in Atrial Fibrillation: Update 2013 Dr. Alexander Trompler, ACCR, Ravensburg, Germany Diagnosis and treatment of pulmonary embolism: Role of echocardiography Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at Pham Ngoc Thach University of Medicine, HELIOS St. Marienberg Hospital Helmstedt, Academic Hospital of the University Magdeburg, Germany Gender-specific aspects in the therapy of cardiovascular diseases Prof. Dr. Hans-F. Voehringer, DRK Kliniken Berlin, Germany Does OCT replace IVUS in the cath lab – what do we need for intervention? Dr. Klaus Schlotterbeck, FESC, MBA, Cardiovascular Center (ACCR), Ravensburg, Germany Which stenosis should be treated? Lessions learned from coronary physiology Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany Surgery in acute endocarditis PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Treatment modalities for severe aortic stenosis - New technologies PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Faculty: PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Prof. Dr. Thomas Budde, Medical Clinic I, Department of Cardiology, Alfried Krupp Hospital, Essen, Germany Dr. Birgit Gerecke, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany Prof. Dr. Georg Dieter Kneissl Johannes Gutenberg-University Mainz, Germany Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at the Pham Ngoc Thach University of Medicine /HCM City, Academic Hospital HELIOS St. Marienberg Helmstedt, Germany Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Dr. Klaus Schlotterbeck, Cardiovascular Center (ACCR), Ravensburg, Germany Dr. Alexander Trompler, Cardiovascular Center (ACCR), Ravensburg, Germany Prof. Dr. Dr. Reinhard Urban, Johannes Gutenberg-University Mainz, Germany Prof. Dr. Hans-F. Voehringer, DRK Kliniken Berlin, Germany 13. VIETNAMESE GERMAN HEART DAYS
Ho Chi Minh City 25.11.2013 Organization:
Lectures: Latest Important Clinical Trials in Cardiology (2012-2013) - An Overview Prof. Dr. Thomas Budde, Medical Clinic I, Department of Cardiology, Alfried Krupp Hospital, Essen, Germany Update on Differentiated Diagnosis and Risk Stratification of (Coronary) Heart Disease with a Special Focus on CT and MRI Prof. Dr. Thomas Budde, Medical Clinic I, Department of Cardiology, Alfried Krupp Hospital, Essen, Germany Noncompaction-Cardiomyopathy- Results of the German-NCCM-Registry Dr. Birgit Gerecke, Prof. Dr. Rolf Engberding, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Indications for device therapy: update of ICD therapy , pacing and resynchronisation therapy 2013 Dr. Birgit Gerecke, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Endoscopically guided ablation of the pulmonary veins: a new approach in catheter based therapy of atrial fibrillation Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Ablation of ventricular tachycardia: An overview Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Pacemaker, ICD und CRT-D: newest guidelines, developments Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Anticoagulation in Atrial Fibrillation: Update 2013 Dr. Alexander Trompler, ACCR, Ravensburg, Germany Diagnosis and treatment of pulmonary embolism: Role of echocardiography Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at Pham Ngoc Thach University of Medicine, HELIOS St. Marienberg Hospital Helmstedt, Academic Hospital of the University Magdeburg, Germany Gender-specific aspects in the therapy of cardiovascular diseases Prof. Dr. Hans-F. Voehringer, DRK Kliniken Berlin, Germany Does OCT replace IVUS in the cath lab – what do we need for intervention? Dr. Klaus Schlotterbeck, FESC, MBA, Cardiovascular Center (ACCR), Ravensburg, Germany Which stenosis should be treated? Lessions learned from coronary physiology Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany Surgery in acute endocarditis PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Treatment modalities for severe aortic stenosis - New technologies PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Faculty: PD Dr. med Pascal André Berdat, Department of Cardiovascular Surgery, Clinic in Park, Zurich, Switzerland Prof. Dr. Thomas Budde, Medical Clinic I, Department of Cardiology, Alfried Krupp Hospital, Essen, Germany Dr. Birgit Gerecke, Medical Clinic I, Department of Cardiology, Academic Hospital Wolfsburg, Germany Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany Prof. Dr. Georg Dieter Kneissl Johannes Gutenberg-University Mainz, Germany Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at the Pham Ngoc Thach University of Medicine /HCM City, Academic Hospital HELIOS St. Marienberg Helmstedt, Germany Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Köln, Germany Dr. Klaus Schlotterbeck, Cardiovascular Center (ACCR), Ravensburg, Germany Dr. Alexander Trompler, Cardiovascular Center (ACCR), Ravensburg, Germany Prof. Dr. Dr. Reinhard Urban, Johannes Gutenberg-University Mainz, Germany Prof. Dr. Hans-F. Voehringer, DRK Kliniken Berlin, Germany |
Archiv
August 2024
|
RSS Feed
Proudly powered by Weebly